GeneOne Life Science Inc Cash Flow Conversion Efficiency

Latest as of March 2026: -0.056x

GeneOne Life Science Inc cash flow conversion efficiency. Based on the latest financial reports, GeneOne Life Science Inc (011000) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.84 Billion ≈ $-1.92 Million USD) by net assets (₩51.15 Billion ≈ $34.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GeneOne Life Science Inc (2013–2025)

Cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2025. This chart illustrates how GeneOne Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of GeneOne Life Science Inc for real-time trading data and today's change.

GeneOne Life Science Inc Cash Flow Conversion Ratio Explained

GeneOne Life Science Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GeneOne Life Science Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GeneOne Life Science Inc ranked by their cash flow conversion efficiency. Also see GeneOne Life Science Inc stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Tera Software Limited NSE:TERASOFT	-0.055x
Resaas Services Inc V:RSS	-0.049x
Minetech Resources Bhd KLSE:7219	0.075x
Investment and Trading of Real Estate JSC VN:ITC	N/A
Velocity Minerals Ltd V:VLC	0.852x
Cipherlab Co Ltd TWO:6160	-0.064x
Toplus Global Co Ltd TWO:3522	-0.092x
Laird Superfood Inc NYSE MKT:LSF	0.006x

Annual Cash Flow Conversion Efficiency for GeneOne Life Science Inc (2013–2025)

The table below shows the annual cash flow conversion efficiency of GeneOne Life Science Inc from 2013 to 2025. Review 011000 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩40.90 Billion ≈ $27.72 Million	₩-16.54 Billion ≈ $-11.21 Million	-0.404x	-115.61%
2024-12-31	₩85.61 Billion ≈ $58.01 Million	₩-16.06 Billion ≈ $-10.88 Million	-0.188x	+3.82%
2023-12-31	₩111.49 Billion ≈ $75.55 Million	₩-21.74 Billion ≈ $-14.74 Million	-0.195x	-46.78%
2022-12-31	₩181.47 Billion ≈ $122.98 Million	₩-24.11 Billion ≈ $-16.34 Million	-0.133x	-462.98%
2021-12-31	₩205.45 Billion ≈ $139.23 Million	₩-4.85 Billion ≈ $-3.29 Million	-0.024x	+85.39%
2020-12-31	₩98.51 Billion ≈ $66.76 Million	₩-15.92 Billion ≈ $-10.79 Million	-0.162x	-206.09%
2019-12-31	₩24.06 Billion ≈ $16.31 Million	₩-1.27 Billion ≈ $-860.67K	-0.053x	+78.64%
2018-12-31	₩29.41 Billion ≈ $19.93 Million	₩-7.27 Billion ≈ $-4.93 Million	-0.247x	-123.54%
2017-12-31	₩36.54 Billion ≈ $24.76 Million	₩-4.04 Billion ≈ $-2.74 Million	-0.111x	+68.00%
2016-12-31	₩35.85 Billion ≈ $24.30 Million	₩-12.39 Billion ≈ $-8.40 Million	-0.346x	-1850.57%
2015-12-31	₩39.44 Billion ≈ $26.73 Million	₩778.50 Million ≈ $527.58K	0.020x	+116.49%
2014-12-31	₩34.73 Billion ≈ $23.54 Million	₩-4.16 Billion ≈ $-2.82 Million	-0.120x	-20.95%
2013-12-31	₩23.71 Billion ≈ $16.07 Million	₩-2.35 Billion ≈ $-1.59 Million	-0.099x	--

About GeneOne Life Science Inc

KO:011000 Korea Biotechnology

Market Cap

$32.81 Million

₩48.42 Billion KRW

Market Cap Rank

#23251 Global

#1590 in Korea

Share Price

₩2670.00

Change (1 day)

+0.00%

52-Week Range

₩534.00 - ₩2670.00

All Time High

₩37651.62